Our Blog
Blog Post
Update from the top: FDA’s Office of New Drugs ongoing reorganization process
What does the FDA’s Office of New Drugs ongoing reorganization process mean for you? Read the latest on what transpired at CBI’s Rare Disease Clinical Development & Access conference in Washington to find out.
Blog Post
Is a Target Product Profile Worth the Effort?
Perhaps the greatest value of the TPP is as a communication tool. The ultimate goal of the development program is shared clearly and continually with all the company disciplines, e.g., clinical, preclinical, chemistry manufacturing and controls, regulatory, and marketing. The TPP is also able to be used as an external communication tool that facilitates interactions with regulatory authorities, investors, and the media.
Blog Post
Orphan Drug Development and Single Trials
Since the enactment of the Orphan Drug Act in 1983, the number of orphan drug approvals has risen steadily. Rho has received an increasing number of sponsor requests for support of programs working towards an orphan drug approval. Can a product be approved with support from a single trial? To better understand when a single trial approval is possible, we look to FDA guidances.
Blog Post
North American Cystic Fibrosis Conference: Key Takeaways
The 33rd Annual NACF conference continues to be an action packed 3 days bringing together scientists, clinicians, health care providers, and caregivers to discuss the latest advances in CF research, care, and drug development. These are our top 3 takeaways from the meeting and how they will impact clinical research moving forward.
Blog Post
Patient-Focused Drug Development: Incorporating the Patient’s and Caregivers’ Perspectives into Product Development
Patient-centricity and family-centricity has been a hot topic for the past few years in clinical research, as more groups in pharmaceutical companies and CROs are working on patient engagement and patient-centric approaches to clinical research programs. Recruitment and retention are one part of patient-centricity, but the more important up-front and overarching aspect of patient-centric research comes from Patient-Focused Drug Development (PFDD).
Blog Post
FDA’s Project Orbis: Trendsetter or One-off
With the announcement of Project Orbis, FDA’s Oncology Center of Excellence (OCE) excited both patients and the pharmaceutical industry with the program’s future possibilities for collaborative regulatory authority interaction in accelerating product approvals worldwide. Is this the tip of the iceberg for process improvement?
Blog Post
Risk Evaluation and Mitigation Strategies: FDA Guidances for Assessing Effectiveness
In January 2019, the Food and Drug Administration (FDA) released 2 draft guidance documents regarding assessment of Risk Evaluation and Mitigation Strategies (REMS). . These documents are meant to provide industry additional information to more accurately assess the effectiveness of their REMS.
Blog Post
Master Protocols and the New FDA Guidance
In September of 2018, FDA released a new FDA guidance on master protocols. So, what are master protocols, how can they benefit sponsors and patients, and what are the challenges? Kevin Barber shares his thoughts and expertise on the topic.
Blog Post
Patient Reported Outcomes and the Common Terminology Criteria for Adverse Events (CTCAE)
The Common Terminology Criteria for Adverse Events (CTCAE) was developed to standardize reporting of adverse events (AEs). In order to integrate the patient’s perspective into AE reporting, the NCI developed a patient-reported outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).
Blog Post
Accentuate the. . . Negative: The Importance of Publishing Negative Clinical Study Results
Negativity often gets a bad rap, but not when it comes to scientific research. Jamie Chang discusses how focusing on the negative can bring about positive advances in clinical research.